Daniel Warnell Lee III, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

University Of Virginia School Of Medicine - Charlottesville VA
Rank: Assistant Professor
Years: 2016 - 2023

University Of Virginia School Of Medicine - Charlottesville VA
Rank: Associate Professor
Years: 2023 - Present

National Cancer Institute
Rank: Assistant Clinical Investigator
Years: 2012-2016

How I Treat: Current concepts in the diagnosis and management of cytokine release syndrome.
Blood
124(2):188- 95
Date: 08 2014

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose-escalation trial
Lancet
385(9967):517-28
Date: 10 2014

CD22- CAR T cells induce remissions in CD19-CAR naïve and resistant B-ALL
Nature Medicine
Volume: 24(1)
Date: 01 2018

Durable regression of medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells
Journal for the Immunotherapy of Cancer
Volume: 6(1)
Date: 04 2018

Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques
Blood
Volume: 132(6)
Date: 06 2018

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
Biology of Blood and Marrow Transplantation
Volume: 25(4)
Date: 04 2019

The Society for Immunotherapy of Cancer Consensus Statement on Immune Effector Cell-Related Adverse Events
Journal of Immunotherapy for Cancer
8(2):e001511
Date: 12 2020

Long-term follow-up of CD19 CAR T-cell therapy in children and young adults with B-ALL
Journal Clinical Oncology
Volume: 39(15)
Date: 01 2021

Targeting of the alphav beta3 integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma
Journal of Immunotherapy for Cancer
10:e003816
Date: 01 2022
10.1136/jitc-2021-0038166(1):30

Three-year results from phase 1 of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
Haematologica
Volume: 108(3)
Date: 10 2022
10.3324/haematol.2022.280678